Literature DB >> 26248118

Natural history of liver disease and effect of hepatitis C virus on HIV disease progression.

Patrick Ingiliz1, Jürgen K Rockstroh.   

Abstract

PURPOSE OF REVIEW: Due to high prevalence rates, the hepatitis C virus (HCV) and the HIV cause two viral infections of global importance. Shared routes of transmission lead to a high number of dually infected individuals especially in specific populations such as intravenous drug users or people from highly endemic regions for both viruses. Treatment progress made in the field of HIV in the past three decades diminished the number of HIV patients who die from opportunistic infections and enabled a rise of HCV-associated liver disease in the HIV-HCV-coinfected population. RECENT
FINDINGS: An HIV-HCV coinfection is mainly characterized by a faster progression to liver cirrhosis that may lead to hepatic decompensation or the development of hepatocellular carcinoma (HCC). The treatment of HIV with highly active antiretroviral therapy (HAART) may only partly reverse this effect by the restoration of the immune system. Although no clear deleterious effect of HCV on the course of HIV infection is described, an increased HIV-associated and non-HIV-associated mortality has been described in patients not cured from their HCV infection.
SUMMARY: In this article, we review the latest knowledge on the natural course of HCV in the HIV-infected population, the role of HIV treatment, and the possible effects of HCV on HIV disease progression.

Entities:  

Mesh:

Year:  2015        PMID: 26248118     DOI: 10.1097/COH.0000000000000187

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  7 in total

1.  The syndemic effect of HIV/HCV co-infection and mental health disorders on acute care hospitalization rate among people living with HIV/AIDS: a population-based retrospective cohort study.

Authors:  Martin St-Jean; Hiwot Tafessu; Kalysha Closson; Thomas L Patterson; M Ruth Lavergne; Julius Elefante; Lianping Ti; Mark W Hull; Robert S Hogg; Rolando Barrios; Jean A Shoveller; Julio S G Montaner; Viviane D Lima
Journal:  Can J Public Health       Date:  2019-08-22

2.  Both HCV Infection and Elevated Liver Stiffness Significantly Impacts on Several Parameters of T-Cells Homeostasis in HIV-Infected Patients.

Authors:  Clara Restrepo; Beatriz Álvarez; José L Valencia; Marcial García; María A Navarrete-Muñoz; José M Ligos; Alfonso Cabello; Laura Prieto; Sara Nistal; María Montoya; Miguel Górgolas; Norma Rallón; José M Benito
Journal:  J Clin Med       Date:  2020-09-15       Impact factor: 4.241

3.  HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients.

Authors:  Amanda Fernández-Rodríguez; Salvador Resino; Óscar Brochado; Isidoro Martínez; Juan Berenguer; Luz Medrano; Juan González-García; María Ángeles Jiménez-Sousa; Ana Carrero; Víctor Hontañón; Jordi Navarro; Josep M Guardiola
Journal:  J Biomed Sci       Date:  2021-03-30       Impact factor: 8.410

4.  HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.

Authors:  Óscar Brochado-Kith; Isidoro Martínez; Juan Berenguer; Juan González-García; Sergio Salgüero; Daniel Sepúlveda-Crespo; Cristina Díez; Víctor Hontañón; Luis Ibañez-Samaniego; Leire Pérez-Latorre; Amanda Fernández-Rodríguez; María Ángeles Jiménez-Sousa; Salvador Resino
Journal:  Front Immunol       Date:  2021-08-23       Impact factor: 7.561

5.  Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub-study A5334s.

Authors:  Charles S Venuto; Yoninah S Cramer; Susan L Rosenkranz; Mark Sulkowski; David L Wyles; Daniel E Cohen; Jeffrey Schmidt; Beverly L Alston-Smith; Gene D Morse
Journal:  Br J Clin Pharmacol       Date:  2019-12-12       Impact factor: 4.335

6.  Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study.

Authors:  Alejandro Alvaro-Meca; Pablo Ryan; Dariela Micheloud; Angel De Miguel; Juan Berenguer; Salvador Resino
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

7.  Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study.

Authors:  Soraia M Machado; Aline G Vigani; Andrea G Leite; Ana Claudia M Diaz; Paulo Roberto A Ferreira; Dimas Carnaúba-Júnior; Simone B Tenore; Carlos Eduardo Brandão-Mello; Mario P Gonzalez; Fabiana Siroma; Kleber D Prado; Delzi V Nunes; Gaspar Lisboa-Neto; João Renato R Pinho; Fernanda M Malta; Raymundo S Azevedo; Steven S Witkin; Maria Cássia Mendes-Correa
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.